Electronic Supplementary Material No.1

DRUG SAFETY JOURNAL

Targeted Spontaneous Reporting of suspected renal toxicity in patients undergoing Highly Active Anti-Retroviral Therapy in two public health facilities in Uganda.

Helen Ndagije¹, Victoria Nambasa¹, Elizabeth Namagala², Huldah Nassali¹, Dan Kajungu³, Gordon Sematiko¹, Sten Olsson⁴, Shanthi Pal⁵

¹National Pharmacovigilance Centre, National Drug Authority, Kampala Uganda

²STD/AIDS Control Program, Ministry of Health, Kampala Uganda

³Institute of Health and Society (IRSS), Universite Catholique de Louvain, Brussels, Belgium

⁴World Health Organisation Collaborating Centre for International Drug Monitoring, Uppsala, Sweden

⁵World Health Organisation

Corresponding Author: Helen Byomire Ndagije, <u>hbyomire@nda.or.ug</u>

Figure 1. Job aid for identificatying and reporting suspected renal toxicity related to tenofovir

TENIFOVIR RENAL TOXICITY ASSESSMENT AID





- Review the patient's medical and drug history.
- Probe whether the patient took the medicines correctly (dose and time)
- · Ask patient if she/he has any complaints after the last visit
- Remember TDF causes renal tubular dysfunction which is typically asymptomatic. Key measurements of interest are urinalysis (protein & glucose in urine) and Serum creatine
- You may consider late symptoms of renal toxicity (fatigue, weakness, frequent urination, increased thirst, edema)



- If laboratory tests were done, compare results with baseline.
- Determine the time between taking the medicine and onset/detection of reaction.
- Rule out any other possible cause of abnormal tests or complaints.



INVESTIGATIONS

For patients initiating Tenofovir, consider baseline tests for glucosuria, protenuria, plasma urea, serum creatinin.

For patients continuing with Tenofovir consider carrying out urinalysis every three months in the first year of therapy and then subsequently on a twice yearly basis or as per the national guideline for monitoring Tenofovir toxicity.





- From your assessment, make a diagnosis for the event whether medicine related or other causes.
- Clinically manage the patient.

REPORT THE SUSPECTED ADVERSE DRUG REACTION

- Fill in the adverse reaction form.
- Send the filled form to the Pharmacovigilance Coordinator or National Drug Authority Plot 46/48 Lumumba Avenue.





